| Literature DB >> 33957703 |
Mei Yang1, Xiaojian Jia1, Hongying Zhou1,2, Ping Ren1, Huan Deng3, Zhi Kong1, Chunyu Xie1, Wenjun Hu1, Wentao Jiang1, Wentao Lai1, Bin Zhang4, Min Zhao5, Tiebang Liu1.
Abstract
Methamphetamine (MA)-associated psychosis (MAP) is highly debilitating and common among individuals who use the drug, yet the underlying neural mechanism is not clear. This study compared brain functions between patients with MAP and those with schizophrenia during resting state and investigated the effect of brain alteration on the association between MA use and psychosis in patients with MAP. Three groups, including 24 patients with MAP, 17 with schizophrenia in first-episode (SCZ) and 31 healthy controls (HCs), were included after receiving a resting-state functional MRI scan. The severity of psychosis was assessed with Positive and Negative Syndrome Scale (PANSS). Imaging data were analysed using regional homogeneity (ReHo) to measure individual's brain function. Compared with the HC subjects, the MAP and SCZ groups had significantly lower ReHo in the cortical regions including left postcentral cortex, right superior temporal gyrus and right rolandic operculum, while had higher ReHo in the left putamen, with brain dysfunctions being more pronounced in the SCZ group. Among the MAP subjects, a mediating effect of ReHo in the right superior temporal gyrus was found on the association between MA use frequency and PANSS positive score. MAP and schizophrenia had a common trend of brain alteration, with the dysfunction being more pronounced in schizophrenia. This finding implicated that MAP might be a condition with neuropathology approaching schizophrenia. The observed critical role of right superior temporal deficit between MA use and psychosis proposed a potential target for interventions.Entities:
Keywords: functional MRI; mediation effect; regional homogeneity; superior temporal gyrus
Mesh:
Substances:
Year: 2021 PMID: 33957703 DOI: 10.1111/adb.13044
Source DB: PubMed Journal: Addict Biol ISSN: 1355-6215 Impact factor: 4.280